This novel cell type was induced from mesenchymal stem cells (MSCs) with natural compounds without genetic manipulation and demonstrated the ability to differentiate into endoderm, mesoderm and ectoderm. However this novel cell free from tumorigenicity and immunogenicity.
This nove cell which is called KHCs. We world’s first discovered KHCs which is pluripotent stem cells without tumorigenicity.
KHCs has over 90% conversion rate from umbilical cord mesenchymal stem cells to KHCs.
Moreover, these cells exhibited increased expression of down-aging and tumor-suppressor genes, transcription factors essential for blastocyst formation, and cytotoxic T-cell markers, while significantly inhibiting cancer cell survival and invasion. In addition, KHCS will have a large number of down-age markers, which will not only extend the healthy lifespan of humans, but will also be a game changer that will change the paradigm of humanity.
Their characteristics enable scalable production and commercialization in an off-the-shelf format. Because we can use allogenic and autologous source (umbilical cord, adipose tissue, bone marrow). Additionally, they have the potential to play a significant role in the prevention and treatment of solid cancer, aging-related diseases and incurable disease.
Stem cell differentiate into various cell types and play a crucial role in regenerative medicine and cell therapy. Embryonic stem cells (ESCs)possess pluripotency but face ethical and immunological issues while induced pluripotent stem cells (iPSCs) overcome ethical concerns but are associated with genetic instability and tumorigenicity.
KHCS is a cell that not only overcomes tumorigenicity and ethical problems, but also suppresses tumor and even kills tumor, and has the ability to differentiate 3germ layers. KHCs will open a new chapter in the treatment of cancer or incurable diseases.
